Moreover, serum levels of IL-6 were demonstrated to correlate with tumor burden in Sézary syndrome and with clinical stage in non-leukemic CTCL [31]. This evidence concerns the gene IL6 and primary cutaneous T-cell non-Hodgkin lymphoma.